Kidney Transplantation Clinical Trial
Official title:
Infrared Image Guided Minimally Invasive Live Donor Kidney Donation for Kidney Transplantation
Verified date | June 17, 2008 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will evaluate the differences between open surgical kidney donation and
laparoscopic kidney donation on kidney donors and recipients. Both procedures are standard
surgeries used to remove kidneys for donation, and they are done equally often. Open surgical
kidney donation involves removing the donor kidney through a 3- to 5-inch surgical incision.
Laparoscopic donation involves making several small holes in the skin and removing the kidney
through a larger hole, while directly watching the kidney with a camera. The study will
correlate the effects of both procedures with donor and recipient kidney function, urine
output, post-operative pain, and return to work after surgery.
Adults without kidney disease who are willing to donate a kidney to a patient enrolled in a
clinical transplant protocol at the NIH Clinical Center may be eligible for this study.
Donors and recipients must be enrolled in the NIDDK protocol, Live Donor Renal Donation for
Allotransplantation (protocol #99-DK-0107).
Donors and patients undergo the following procedures:
- Infrared imaging (measurement of small differences in temperature using a special
camera) during surgery to look at blood flow to the kidney during the operation (both
donor and recipient surgical procedures). The pictures provide images of the blood
vessels in the kidney and measure how the blood flow changes.
- Kidney biopsy (removal of a small piece of kidney tissue). The patient's failed kidney
is biopsied once during transplant surgery when it is removed. The donor's kidney is
biopsied twice - once during surgery to remove the organ from the donor and again after
transplant into the recipient.
- Evaluations after surgery of post-operative urine output, blood pressure, and pain, and
length of hospital stay and return to work.
Status | Completed |
Enrollment | 40 |
Est. completion date | June 17, 2008 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: Patients enrolled in the Live Donor Renal Donation for Allotransplantation 99-DK-0107. EXCLUSION CRITERIA: Patients ineligible for this protocol will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Tarantino A. Why should we implement living donation in renal transplantation? Clin Nephrol. 2000 Apr;53(4):suppl 55-63. Review. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 |